NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2080.40 9.00 (0.43%)

78,488 NSE+BSE Volume

NSE 28 Nov, 2025 10:26 AM (IST)

95,024.8

Market Cap

High in industry

Beta 1Year

Low volatility

Analyst Upgrade

Geojit BNP Paribas upgrades Lupin to a 'Buy' call, expects a revenue CAGR of 10.2% over FY26-27 See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

07 Aug 2025

2080.40

0.43%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We recommend a BUY rating with a target price of Rs 2,500/share.

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

03 Jul 2025

2080.40

0.43%

Lupin (BUY): Lupin carves out Consumer Healthcare business

Buy: Lupin Ltd.

BOB Capital Markets Ltd.

LPC's OTC carve-out won't significantly impact financials, but aims to double OTC sales by sharpening focus

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

16 May 2025

2080.40

0.43%

Lupin (LPC IN) Q4FY25 Result Update Strong US...

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

Lupin's (LPC) Q4FY25 EBITDA was at Rs13bn (up 30% YoY) ~10% beat to our estimates on the back of higher US sales supported by niche launches. GMs improved YoY. LPC saw remarkable turnaround in profitability with ~2x jump in EBITDA over FY23-24 aided by better product mix, continued niche launches in the US, clearance from USFDA for facilities, domestic formulations regaining momentum and cost optimization measures. We expect margins to sustain given a strong pipeline in the US. Our FY26E stands increase by 5% as we factor...

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

15 May 2025

2080.40

0.43%

Niche products and superior execution lead to robust 4Q and FY25 performance

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered slightly better-than-expected revenue, EBITDA, and PAT for the quarter (4% beat). LPC continues to track well in the US generics segment (40% of 4Q sales), clocking the highest quarterly run-rate of USD245m over the past 24 quarters.

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

13 Mar 2025

2080.40

0.43%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

13 Feb 2025

2080.40

0.43%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

13 Feb 2025

2080.40

0.43%

LUPIN LTD

Buy: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

13 Feb 2025

2080.40

0.43%

Lupin (BUY): High-margin US region to have growth visibility till FY27

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

US sales cc quarterly run rate at its highest-ever level of US$ 235mn, expect to inch up to US$ 250mn in FY26E and US$ 280mn in FY27E

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

30 Dec 2024

2080.40

0.43%

Delay in approval for Amneal's gProAir an unexpected positive

Buy: Lupin Ltd.

Emkay

In Teva’s litigation with Amneal which blocked Amneal’s launch of gProAir, the US Court of Appeals had recently asked Teva to delist its patents in contention. While the ruling was expected to clear the way for Amneal’s launch of gProAir, Teva has now filed a petition seeking an en banc rehearing.